Increased Platelet Destruction in Infancy and
The number of platelets in the peripheral blood of healthy children, 96 full-term, 5 ,1 and premature infants 1, 72 falls into the same range as that of adults. Thrombocytopenia, defined as a platelet count of less than 150,000/mm 3 (<150 × 10 9 /L), may be due to decreased production, splenic sequestration, or increased platelet destruction. The following is a review of disorders involving the last mechanism, all of which have the common feature of reduced autologous platelet survival. Excluded from current considerations are inherited disorders in which the survival of allogenic platelets is normal and bleeding is mainly due to diminished platelet production, e.g., Wiskott-Aldrich syndrome, or a defect in platelet function, e.g., Bernard-Soulier syndrome.
Destructive thrombocytopenias may be classified on the basis of pathogenesis: these are either immune mediated, nonimmune mediated, or a combination of both. The immune thrombocytopenias may be further divided into disorders of primary type in which there are no identifiable underlying disease processes (e.g., childhood idiopathic thrombocytopenia and neonatal immune thrombocytopenias) and disorders of secondary type in which the thrombocytopenia is associated with an identifiable insult (e.g., secondary autoimmune disorders and drugs). The nonimmune thrombocytopenias include a large group of disorders in which the increased platelet destruction is either surface mediated, e.g., hemolytic-uremic syndrome (HUS), thrombin mediated, e.g., disseminated intravascular coagulation and giant hemangioma, or caused by multiple factors, e.g., necrotizing enterocolitis, hemolytic anemia, exchange transfusion, phototherapy, intrauterine growth retardation, congenital polycythemia, hypoxia, and deficiency of plasma factors. In some disorders, e.g., infection-induced thrombocytopenia, both immune and nonimmune mechanisms have apparently resulted in increased platelet destruction.
Although most forms of thrombocytopenia in children are classifiable as indicated, this is not true for newborn infants. In our own experience 26 and in the relevant literature, 89, 97, 133, 164 60 to 80% of neonates with thrombocytopenia do not have an identifiable basis for this abnormality. This is a large number of infants considering the fact that up to 50% of babies admitted to neonatal intensive care units have thrombocytopenia. 26, 97, 164 
IMMUNE-MEDIATED PLATELET DESTRUCTION
Immune-Mediated Thrombocytopenia of Primary Type
Idiopathic Thrombocytopenic Purpura
Idiopathic thrombocytopenic purpura (ITP), the most common form of thrombocytopenia in children, is a diagnosis made by exclusion. In contrast to adults, 70 to 90% of children have the acute form of ITP 135, 143, 146, 147, 221 in which thrombocytopenia may last from 3 days to 6 months with a mean interval to spontaneous recovery of about 1 month, 38, 146, 147, 153, 221 although approximately 4% of children have subsequent relapses. 221 The less frequent chronic form, defined as thrombocytopenia persisting for longer than 6 months, 153, 175, 221 occurs in only 10 to 15% of cases. 143, 146, 147, 221 Large centers have reported a higher incidence of chronic ITP (30%), but this likely represents the referral pattern to tertiary care facilities. 38 This definition of chronic ITP, although widely used, is quite arbitrary and may not be particularly useful. For example, children who have had acute ITP and who have been in remission for up to 6 years may still exhibit a shortened platelet survival. 186 Further-more, in our experience, children who have had chronic ITP for months or years may recover spontaneously. This has also been reported in adults. 191 Acute ITP in children affects males and females equally and has a peak incidence between 2 and 6 years of age. 38, 42, 143, 146, 147, 247 It occurs predominantly in the winter and spring months 38, 42, 143, 146, 147, 221, 247 and is associated with a preceding viral illness in 50 to 85% of cases. This is usually an upper respiratory tract infection that occurred 1 to 6 weeks earlier. 38, 42, 143, 146, 147, 221, 247 The disorder seems to be less common in black children, an observation that does not appear to be due to difficulty in observing purpura in deeply pigmented skin. 119 ' 147 In more than 90% of instances, the clinical presentation of acute ITP is that of an abrupt, spontaneous development of petechiae and ecchymoses in an otherwise healthy child. Other forms of bleeding include epistaxis (30%), 38, 146, 147, 153 hematuria (5 to 10%), 146, 147, 153 and intracranial hemorrhage (<2%). 38, 143, 146, 147, 153, 221, 252 The incidence of bleeding requiring red blood cell transfusion therapy has been reported to be as high as 20%.
38
Although blood loss may be severe on occasion, the major life-threatening complication of childhood ITP is intracranial hemorrhage. Woerner et al. 252 reviewed the reported cases of intracranial hemorrhage in children with ITP and noted that in 10 of 18 cases, the central nervous system (CNS) bleeding occurred more than 1 month following diagnosis, with one case occurring 5 years later. In addition, six of these patients had platelet counts between 10,000 and 20,000/mm 3 and at least four patients were receiving steroid therapy. The latter observations are important, since part of the rationale for treatment with steroids is that patients with severe thrombocytopenia are at greatest risk in the first month after diagnosis. The location of bleeding may be important, with the posterior fossa incurring a particular risk. Patients who received drugs known to inhibit platelet function, such as aspirin and antihistamines, also appeared to be at greater risk of intracranial hemorrhage.
Physical examination usually reveals only petechiae and ecchymoses. Sixty percent of children have shotty lymphadenopathy 147 and in fewer than 10% is the spleen tip palpable, 147, 153 a prevalence similar to that in normal children. 240 Splenomegaly of greater degree does not occur in acute ITP and, if present, this finding should suggest an alternative diagnosis.
Chronic ITP in childhood is similar to the adult entity and cannot be distinguished reliably from acute ITP on the basis of clinical presentation. 143, 147 It may occur at any age but is more common in older children 147, 221 and females.
38,147, 221,247 Although by definition the disorder is persistent, many affected children attain a hemostatic platelet count, 119, 147 an important consideration when planning specific therapy.
The platelet count is less than 40,000/mm 3 in 80% of children with ITP at presentation 247 and the platelet size is increased significantly, the mean platelet diameter being 1.3-to 1.6-fold greater than normal. 120, 162, 177 These are "young" platelets, the presence of which indicates active thrombopoiesis with an increased platelet turnover. 75 The total white cell count is usually normal; however, a reactive lymphocytosis is common 147 and 20% of children have a mild eosinophilia. Bone marrow examination is undertaken primarily to exclude such disorders as leukemia and hypoplastic anemia. This is essential if steroids are to be used as part of the clinical management. In ITP the bone marrow shows a normal or increased number of megakaryocytes. Morphologic changes, indicating that these are less mature than normal, are fewer nuclear lobes, less cytoplasmic granulation, and a lack of discernable platelet budding; 120, 162 however, these are not specific features of the condition.
Several investigators have studied both the humoral and cellular immune systems in children with acute and chronic ITP. 156, 231 The majority of patients exhibited immunologic abnormalities, including autoantibodies and abnormalities in complement, immunoglobulins, or regulatory lymphocytes. 156 It is important to measure antinuclear antibody in each patient at presentation and to repeat the measurement in those who follow a chronic course, since systemic lupus erythematosus (SLE) may present with thrombocytopenia. There are no laboratory tests that can accurately predict whether an individual child will have acute or chronic ITP. Chronic ITP has been associated with a low level of immunoglobulin A (IgA) 147 less platelet-associated IgG, 142 and increased basal thymidine incorporation in lymphocytes. 231 When steroids are to be used in the management of a child, it is important to establish that he or she does not have tuberculosis, and to determine if he or she has been exposed recently to the varicella zoster virus.
Historically, ITP was thought to result from a failure of platelet production due to disordered megakaryopoiesis. Harrington and co-workers 94 demonstrated that plasma from patients with ITP, when infused into a normal subject, produced severe thrombocytopenia. Only one of these patients was less than 12 years of age. Shulman et al. 220 established the immune nature of chronic ITP in adults by demonstrating that the causal circulating plasma factor was IgG. 220 Since that time, several investigators have developed assays 8, 94, 100, 117 that confirm that 70% of adults with chronic ITP have a platelet antibody in their serum. In children, accounts have varied greatly, with 12 to 88% having detectable antibody using these techniques. 117 142 found elevated levels of plateletassociated IgG (PAIgG) in 13 chronic and 7 acute cases of ITP in children. The investigators also noted that the children with chronic ITP had significantly lower levels of PAIgG than did those with acute ITP. 142 In the acute cases, PAIgG returned to normal with spontaneous clinical recovery. It was hypothesized that, in the acute disease, immune complexes form during an antibody response to an infection and bind to the circulating platelets. In chronic ITP, the lesser amounts of IgG bound to platelets may represent antibody directed against a specific platelet antigen.
The site of antibody production in acute ITP in children has not been determined. However, in adults with chronic ITP, the spleen is an important source of platelet-binding IgG. 121, 159 It is interesting to note that this antibody has also been shown to bind to homologous megakaryocytes and it may alter thrombopoiesis. 161 The spleen is a major site of platelet destruction; 11, 181 however, the liver has been implicated as well, particularly in severe thrombocytopenia 11 with high levels of PAIgG. 11, 17 Recently, the clinical usefulness of PAIgG determinations has been called into question, 129 since increased levels of PAIgG have been measured in patients with supposedly nonimmune-mediated thrombocytopenia.
Management of childhood ITP may be divided into supportive measures and specific therapeutic intervention. The former consist of replacing blood loss by transfusions when necessary, avoiding all drugs that inhibit platelet function, including cough mixtures containing glyceryl guaiacolate, and resisting physical activity (swimming is allowed but diving is not). Specific therapeutic intervention includes the use of corticosteroids, infusion of platelets, plasma, or immunoglobulin preparations, and occasionally resorting to immunosuppressive agents or splenectomy.
The use of corticosteroids in childhood ITP is highly controversial. The interval to recovery has been considered to be shortened 221 or lengthened 38 ' 147 with the use of these agents. There are also conflicting reports on the impact of a course of such therapy on the natural history of the disease, both detrimental 38, 139, 147, 153 and beneficial 221 effects having been recorded; however, these were uncontrolled trials. In controlled clinical trials, the use of steroids did appear to abbreviate the initial duration of thrombocytopenia. 163 ' 205 Administration of steroids to normal individuals had no effect on platelet survival or platelet count. 220 Nevertheless, there are at least three mechanisms by which steroids can decrease the hemorrhagic diathesis in patients with ITP. 24, 31, 85, 86, 132 Recent work by Blajchman et al. 24 indicated that injured vessel walls release prostaglandins that relax smooth muscle. Steroids inhibited this response and so facilitated hemostasis by promoting vasoconstriction. Secondly, the sequestration of damaged or antibody-coated platelets by the spleen was decreased by corticosteroids. 85, 141, 160, 197, 206, 241 Finally, these agents inhibited the production of antibody to a previously recognized antigen, 31, 86, 203 although it is doubtful whether this is accomplished by conventional doses of corticosteroids. Despite the controversy surrounding the administration of steroids, these are relatively safe drugs that are used in more or less selected circumstances, at the discretion of the responsible physician, for children who are thought to be at risk of severe hemorrhage. The usual dose is 2 mg/kg/day in divided doses for a period of 1 to 4 weeks, 119, 143, 147 as is our practice. Temporary recurrence of thrombocytopenia can occur when steroid therapy is stopped. 119, 147, 153, 221 There is no evidence that long-term steroid therapy is of benefit, and indeed this may cause persistent thrombocytopenia 44 and hypertension, which has been implicated in the pathogenesis of intracranial hemorrhage occurring in patients on corticosteroid therapy.
Platelet transfusions have a very limited role in the management of ITP. The infused platelets are destroyed rapidly and rarely lead to a detectable rise in the platelet count. 153 However, this modality may be helpful in the management of intracranial bleeding. 252 Both plasma 209, 210 and gamma globulin infusions 107, 108 may cause a rise in the platelet count in some individuals with ITP, although the mechanism is unknown. Neither of these maneuvers is recommended as the initial management of a child with acute ITP, but may be useful in some children with the chronic variant. The use of plasmapheresis in children with ITP has been reported 25 and may be temporarily effective. Of all children with chronic ITP, approximately one-third maintain platelet counts in excess of 50,000/mm 3 , have few or no bleeding episodes, and do not require splenectomy. 147 However, others will have clinically significant bleeding and may benefit from removal of the spleen. The decision to perform a splenectomy should be postponed, if possible, until the child is at least 4 years of age. 143, 147 Pneumococcal vaccine should be given and steroids administered perioperatively. Platelets should be available in case of uncontrolled bleeding. 147 Usually the platelet count rises rapidly as soon as the splenic pedicle is clamped. 147 Because of reported failures with the use of pneumococcal vaccine, some centers are using daily oral penicillin prophylaxis as well 55 in a concerted effort to reduce the risk of fatal postsplenectomy infection. The response rate to splenectomy in children with ITP is 55 to 85%, which is similar to that in adults. 147 Another 10 to 20% have a sustained rise in the platelet count to levels at which excessive bleeding does not occur (60,000 to 100,000/mm 3 ). Unfortunately, 10 to 20% derive no benefit from splenectomy. Usually these patients did not respond initially to steroids.
Immunosuppressive agents should be reserved for the few children who have serious bleeding despite all other modes of treatment. The agents that have been used in children are azathioprine. 99, 137,205 cyclophosphamide, 147 vincristine, 3, 98, 150 and vinblastine. 4, 223 Of these, vincristine and azathioprine have been employed most extensively. Between 50 and 60% of children with chronic ITP respond with a rise in the platelet count, 98, 150 but this is usually short-lived. All of these agents have potentially serious side effects that are of particular importance in young children. In addition, vincristine has been reported to cause platelet dysfunction that, at least theoretically, may predispose to further bleeding. 226 The management of a thrombocytopenic child who suffers an intracranial hemorrhage has been summarized by Woerner et al. 252 In brief, this includes a computed tomography scan to localize the lesion, supportive measures to control increased intracranial pressure, high-dose steroids (4 mg/kg/ day), emergency splenectomy prior to neurosurgical intervention, appropriate neurosurgical intervention if necessary, and platelet transfusions, which should be used if the platelet count does not rise after splenectomy. Fortunately, more than 50% of children who have endured this life-threatening complication have had a favorable outcome.
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Neonatal Immune Thrombocytopenias
These disorders are conveniently divided into autoimmune and alloimmune variants. The former is a misnomer, since the autoimmune process occurs in the mother and not in the baby, whereas in both variants antiplatelet antibody is delivered transplacentally to the passive fetal recipient and the disorders are therefore self-limiting. Thus, in autoimmune thrombocytopenia of the newborn IgG (subclass 3), 122 from the mother with ITP, crosses the placenta and becomes attached to the infants' platelets. 65 ' 96 ' 188 The clinical presentation is usually that of a healthy, full-term infant who develops petechiae and bruising shortly after birth. The maternal history is very important, since there is often evidence of ITP or another autoimmune disorder. Alternative causes of neonatal thrombocytopenia, such as familial disorders, antenatal drug ingestion, or maternal infection, should be excluded. Investigations include a platelet count in both the mother and the newborn infant. The infant is found to be thrombocytopenic and usually, but not invariably, the mother is as well. If the maternal platelet count is normal, the measurement of PAIgG and serum platelet-bindable IgG (S-PBIgG) may be helpful in distinguishing autoimmune from alloimmune thrombocytopenia. 127 In the former, both the infant and mother have an increased PAIgG, whereas in the alloimmune variant the mother does not have an elevated PAIgG but rather S-PBIgG directed against the infant's platelets.
Neonatal "autoimmune" thrombocytopenia. The obstetrical management of women who are known to have autoimmune thrombocytopenia is the subject of considerable debate. 32, 118, 162, 178, 212 Of major concern is the risk of intracranial hemorrhage in the infant during vaginal delivery. The frequency of this complication has been reported to range from 0 to 25%. 7, 114, 118, 147, 184, 200 Karpatkin et al. 118 reviewed these reports in detail recently and concluded that the figure of 25% is almost certainly an overestimate, since many of the fatalities were spontaneous abortions in the first trimester, 184 stillbirths, and neonatal deaths from other causes with no evidence of hemorrhage. 200 The majority of reports do not record the platelet count at the time of birth. This is an important omission, since the platelet count frequently falls precipitously during the first few hours of life. 188 The decision to perform elective Caesarian section on such women has been based on these studies. More recently, Cines et al. 40 reported that the level of circulating maternal antiplatelet antibody correlated with the development of neonatal thrombocytopenia and may be useful in identifying infants at risk. The several obstetrical options are as follows:
1. Elective Caesarian section for all pregnant women with a history of autoimmune thrombocytopenia. 178 This approach is based on the report of a neonatal mortality rate of 25% following vaginal delivery. 184, 200 2. Elective Caesarian section only for mothers with platelet counts less than 100,000/ mm 3 , 32,162,228 a policy arising from the reported association between the mother's platelet count at delivery and the platelet count in the infant. 228 However, in a more recent study, Scott et al. 212 found no correlation between maternal and fetal platelet counts in 113 pairs of mothers and infants. 3. Elective Caesarian section reserved for all women who have had a splenectomy. 32, 162, 228 This form of management is based on an observation in 1950 that death was more likely to occur in infants whose mothers had undergone splenectomy. 200 There is no good evidence that any of these three approaches is efficacious. The following two observations, however; appear to be promising:
1. Caesarian section if the fetal scalp venous platelet count obtained early in labor is less than 50,000/mm 3 . Using this novel technique, Scott et al. 212 avoided Caesarian section in 9 of 12 women who had ITP. The lowest platelet count in the infants was 72,000/mm 3 . In contrast, three infants were delivered by Caesarian section and all had platelet counts less than 20,000/mm 3 . This approach should be used only in centers that have experience with the sampling technique, for fetal scalp venous blood samples clot readily and may give falsely low platelet counts. 2. Karpatkin et al. 118 advocate the administration of steroids to the mother for 10 to 14 days prior to vaginal delivery. In a controlled series, 12 mothers received steroids and seven did not. The mean platelet count in the infants of the steroid-treated mothers was 151,000/mm 3 (range 65,000 to 399,000), whereas in the infants of untreated mothers it was 42,000/mm 3 (range 12,000 to 112,000).
After birth, the offspring of a mother with ITP should have a platelet count measured every 6 to 8 hours initially. If it is below 80,000 or falling precipitously, corticosteroid therapy should be instituted. In our experience this is usually effective in preventing or controlling hemorrhage, but, if serious bleeding occurs or the platelet count falls below 10,000/mm 3 , infusion of platelet concentrates from random donors or exchange transfusions with fresh blood may be effective in the short term. Splenectomy is contraindicated due to the risk of subsequent serious infection and the self-limiting nature of the disorder. Vincristine 214 has been used, but should only be considered when all other measures have failed. Thrombocytopenia may persist for 4 to 8 weeks.
Neonatal alloimmune thrombocytopenia. The thrombocytopenia results from active immunization of the mother by paternal antigens on the platelets of her fetus. The pathogenesis is analogous to that of Rh hemolytic disease of the newborn but, in contrast to Rh disease, first-born infants are often affected. 118 Although thrombocytopenia may be severe, the maternal platelet count is always normal. In 50 to 75% the maternal antibody is directed against the platelet-specific antigen PL A1 , 218, 244 which is not present on the mother's platelets. Since this is a public antigen (only 2% are PL A1 negative), the disorder is uncommon, affecting only 1 to 2/10,000 live births. 188 ' 218 Other antibodies to platelet-specific antigens which have been implicated are anti-Duzo, 173 anti PL E2 218 and anti Bak a . 245 Anti-HLA antibodies have also been detected but the significance of this finding is uncertain. 244 Identification of platelet-specific antibodies in maternal serum is often difficult, for these do not cause platelet agglutination and seldom bind complement. 218 In a comparison of several methods for detecting antibody in alloimmune thrombocytopenia, von dem Borne et al. 243 found that immunofluorescence of paraformaldehyde-fixed platelets in suspension gave the best results. [237] [238] [239] The radioactive indirect antiglobulin test developed by Soulier and co-workers 224 has also been valuable. We have used the measurement of PAIgG and S-PBIgG to distinguish this disorder from autoimmune thrombocytopenia. 127 The optimal obstetric management of women who have had previous babies with alloimmune thrombocytopenia is uncertain. 7, 74, 188, 189, 222 Of primary concern is that 10 to 14% of such infants have suffered an intracranial hemorrhage. 189, 222 In at least four instances, this event has occurred in utero. 112, 255 On the basis of a 75% recurrence rate in second pregnancies, most investigators advocate elective Caesarian section. The possible benefit of antenatal steroid therapy has not been evaluated.
Following delivery, the treatment of choice for the infant affected by alloimmune thrombocytopenia is an infusion of washed maternal platelet concentrates, 2 ' 155 since the mother's platelets lack the target antigen. If the diagnosis is suspected, platelet concentrates can be prepared prior to delivery. 127 Thrombocytopenia may persist for 1 to 8 weeks and maternal platelet infusions may have to be repeated until the infant's platelet count has stabilized at a safe level (> 50,000/mm 3 ). Other forms of therapy have been used without consistent success. These include administration of steroids to the baby, infusion of platelets from random donors, and exchange transfusion. Splenectomy is clearly contraindicated.
Immune-Mediated Thrombocytopenia of Secondary Type Autoimmune Disorders
Immune-mediated thrombocytopenia is a feature of several autoimmune disorders that occur in children as well as in adults. Temporary thrombocytopenia may also occur in the newborn infant of a mother affected by hyperthyroidism or SLE.
Hyperthyroidism in adults is sometimes complicated by thrombocytopenia. 138 Congenital thyrotoxicosis presents with hepatosplenomegaly and thrombocytopenia. 64, 254 Recently, an infant with congenital thyrotoxicosis at our institution had an elevated PAIgG and responded poorly to infusions of random donor platelets, suggesting that the pathogenesis of thrombocytopenia was immune-mediated platelet destruction. There are also case reports of SLE in the mother causing thrombocytopenia in the infant. 182, 213 In one case, platelet agglutination was demonstrated in the mother and the infant. 182 Administration of steroids to the infant may ameliorate neonatal thrombocytopenia of this type. 
Drug-Induced Platelet Destruction
A major difficulty in evaluating the reports of suspected drug-induced, destructive thrombocytopenia is that the evidence is often circumstantial. However, there are well-documented cases of immune-mediated thrombocytopenia associated with the administration of drugs to infants and children. 19 ' 57 ' 117 ' 151 ' 171 These are relatively infrequent by comparison with the adult experience, probably reflecting the lesser exposure of children to the causal agents, comprehensive lists of which are available in other reviews. 91, 166 In children, anticonvulsants 19, 143, 171, 204 and antibiotics 143 are most commonly implicated. Of the anticonvulsants, valproic acid, a relatively new agent, has been reported to cause an immune-mediated thrombocytopenia that may be dose related in some patients. 204 In our own experience with 45 children receiving this drug, reduction in the platelet count appeared to be immune mediated, as demonstrated by elevated PAIgG determinations, 19, 171 but the pathogenesis was far from clear, since the thrombocytopenia resolved despite continuing drug administration. Evidently the mechanisms involved are more complex than was previously realized. 19 In almost all cases the antibody that is held to be responsible is an IgG, although IgM has been implicated on occasion. 23, 61, 204 There are at least two mechanisms by which the drug-antibody-platelet interaction can occur. The drug or drug metabolite 62 may interact with a plasma protein ("carrier molecule") and evoke an antibody response that is directed against the drug-carrier complex. The resulting antigen-antibody complex then attaches to the platelet nonspecifically, presumably via the Fc receptor; or the drug or its metabolite may attach directly to the platelet surface, the antibody then combining with the drug-platelet complex. 219 In either event, the antibody-coated platelets are then removed from the circulation by the reticuloendothelial system. Several methods are available for detecting the presence of specific drug-dependent platelet antibodies. These include complement fixation, 103, 217 "immunoinjury" techniques, 117, 217 and platelet agglutination. 217 Such methods are preferable to those that measure platelet-bound antibody, since the former can be performed in the presence or absence of the suspected drug. However, Kelton et al. 128 have used a combination of PAIgG and S-PBIgG determinations to demonstrate the increased binding of IgG to platelets, both in vivo and in vitro, in patients with drug-induced thrombocytopenia.
Reports of drugs being given antenatally to the mother, and purportedly causing thrombocytopenia in the newborn infant, are seldom well documented. An exception is the case of quinine-induced thrombocytopenia in a mother and infant, in both of whom platelet agglutinins were demonstrated. 151 Other drugs that have been implicated are tolbutamide, 207 hydralazine, 251 and the thiazide diuretics. 201 In these instances the pathogenetic mechanism has not been clearly defined, and the association may well be circumstantial. Certainly the role of thiazides is highly controversial. 110, 165, 201 In the original report by Rodriguez et al., 201 three of seven cases were siblings and in one of these pregnancies it was not known whether the mother was receiving thiazide therapy. Such circumstances are more suggestive of an autoimmune or alloimmune process than drug-related thrombocytopenia. Another infant was found to be thrombocytopenic only after suffering a severe apneic episode associated with a grand mal seizure. Since this original report, other investigators have been unable to find an association between maternal thiazide ingestion and thrombocytopenia in the infant. 110, 165 Thus, although drugrelated and immune-mediated thrombocytopenia has occurred in infancy, it is a rare event. 188 Fatal intracranial hemorrhage resulting from druginduced thrombocytopenia has been reported in adults, 56 but not in children. Withdrawal of the offending agent is the treatment of choice and results in a rise in the platelet count usually within a few days.
NONIMMUNE-MEDIATED PLATELET DESTRUCTION
Surface-Mediated Platelet Destruction
Hemolytic-Uremic Syndrome
Hemolytic anemia, acute renal failure, and thrombocytopenia constitute the triad described by Gasser et al. 76 in 1955 as HUS. Since then, there have been numerous case reports and reviews of the subject. 27, 28, 84, 140 The disorder has a peak incidence in early childhood, 28, 79, 130, 233 usually before the age of 4 years, 84 involving males and females equally. Typically, affected infants and children have been previously healthy, except for a preceding mild infection that is usually manifested as nonspecific gastroenteritis or occasionally involvement of the upper respiratory tract. One to 10 days later, pallor, purpura, and oliguria become evident. Melena, hematemesis, and neurologic manifestations occur less frequently. 79, 202 Lethargy, pallor, hepatosplenomegaly, purpura (30 to 40%), and hypertension (50%) are the dominant physical findings. 27 ' 233 The relationship between HUS and thrombotic thrombocytopenic purpura (TTP) is considered elsewhere in this issue. Although TTP is principally a disorder of adult life, it has been reported in infants 167 and older children. 20, 149 In HUS the hemoglobin concentration ranges from 3 to 10 gm/dl and the blood smear reveals evidence of red cell fragmentation. Reticulocyte and total leukocyte counts are often elevated. The direct antiglobulin test is usually negative, 27 ' 116 and the red blood cell enzyme defects have not been demonstrated. 116 Other laboratory evaluations reveal an elevated blood urea nitrogen and serum creatinine, and an abnormal urinalysis (proteinuria, hematuria, casts). Thrombocytopenia is present in virtually all cases, but it is usually mild or moderate in degree. There is general agreement that the severity of the renal involvement dictates the ultimate outcome, 28 ' 84,116 with prolonged anuria and persistent hypertension being associated with a poor prognosis. Although in earlier series a mortality rate as high as 40% was reported, 78 ' 192 improved management of acute renal failure has lowered this to 5 to 10%. 79, 116,233 Long-term problems may result from chronic renal failure, hypertension, neurologic deficits, and recurrence of the disorder.
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Several factors have been implicated in the etiology of HUS, including familial and genetic predisposition, 68, 115, 195, 234 pregnancy, 71,84 viruses, 13 ' 41,53,79,82 bacteria, 16, 70, 84, 157, 196 drugs, 30, 84, 208 and contaminated apple juice. 225 In the latter series, a cohort of 14 children presented within a 10-day period with a wide clinical spectrum of disease, i.e., from severe CNS involvement to only minor renal abnormalities. All of these children had ingested fresh apple cider manufactured locally in a single batch, suggesting that a contaminating organism or toxin was responsible.
It is very likely that diverse insults lead to a common renal injury. The pathology of the lesions in the kidneys has been reviewed extensively. 84 ' 116 ' 242 In brief, the most consistent feature is thickening of the glomerular capillary walls due to an accumulation of periodic acid-Schoff (PAS) positive material in the subendothelial space. 242 Thrombi are seen less frequently. Mechanisms that have been proposed to explain the thrombocytopenia are disseminated intravascular coagulation (DIC), 14, 168, 169, 236 adhesion of platelets to the damaged glomerular capillary wall, 52 platelet aggregation in the kidneys as a result of local intravascular coagulation, 80 and intrarenal platelet injury with subsequent sequestration in the reticuloendothelial system. 125 Although abnormalities of plasma clotting factors have been reported, 14 these values are usually normal, 124, 131, 169 indicating that DIC is not an important mechanism leading to thrombocytopenia in this disorder. Furthermore, although labeled platelets do have a shortened half-life, 125 external counting over the kidneys has failed to demonstrate significant renal pooling. 125 Thus, the most plausible mechanism is platelet injury inflicted by fibrin strands in the renal microcirculation. 84, 116, 125 The care of children with HUS has been reviewed exhaustively in recent articles 28, 84, 116 in which the energetic management of acute renal failure, with the early use of dialysis, is emphasized. Any role for steroids, fibrinolytic agents, anticoagulants, aspirin, or dipyridamole is debatable, and the use of these agents is probably not indicated.
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Thrombin-Mediated Platelet Destruction Disseminated Intravascular Coagulation
Although DIC is an infrequent event in childhood, it occurs in up to 10% of sick infants admitted to a neonatal intensive care unit. 164 The precipitating disorders include obstetrical complications, 22 69 In a series of infants with severe birth asphyxia and cardiovascular collapse at our institution, 256 40% developed hypofibrinogenemia, and two-thirds of these were thrombocytopenic. However, the remainder of the infants who did not develop DIC were at no greater risk than other infants of developing thrombocytopenia in the first 48 hours of life. This suggests that DIC is an important mechanism by which asphyxia causes thrombocytopenia in the newborn. 256 The laboratory diagnosis of DIC in children is the same as in adults. 47, 93, 148, 176 In the neonate, it is essential to compare the results with age-related values. Prolongation of the prothrombin time and partial thromboplastin time is not very helpful, but the thrombin clotting time as a screening test, the fibrinogen concentration, and platelet count are very useful in deciding whether DIC exists. Like-wise, assays of Factors V and VIII, which are normally in the adult range, are commonly reduced when DIC is present.
The most effective treatment for DIC, in both infants and older children, is correction of the underlying disease process. Unless this is accomplished, DIC will usually persist and the outcome is often fatal. 90 Heparin has not been of value in managing DIC in childhood 49,51 and rather may cause further bleeding. Unless there is evidence of widespread thrombosis, we do not recommend the use of heparin. In our experience replacement of coagulation factors and platelets, either by component infusion therapy or exchange transfusion, has been successful in temporarily controlling DIC in the sick neonate, thus allowing time to treat the underlying disorder.
Giant Hemangioma
Giant hemangiomas may cause consumptive coagulopathy with hypofibrinogenemia, thrombocytopenia, and resulting generalized purpura (Kasabach-Merritt syndrome). 92, 144, 215, 229 The vascular tumor is present at birth, may occur anywhere on the body, and is usually large and solitary. Approximately 50% of affected infants experience systemic bleeding during the first month of life. It is believed that platelets are destroyed or sequestered within the tumor, 29, 81, 136 regression of which may occur spontaneously 215, 248 or following the use of steroids 67, 123, 194 or radiation therapy. 59 Surgical excision has also been effective. Hemangiomas of the placenta have caused self-limiting destructive thrombocytopenia at birth. 
Nonimmune-Mediated Thrombocytopenia from Other Causes Necrotizing Enterocolitis
NEC presents in the premature infant with bloody stools, vomiting of bile-stained gastric residue, and abdominal distension. 134 Intramural gas is usually demonstrable radiographically, and the diagnosis is confirmed by histologic examination of the bowel either at autopsy or following surgical resection. The hematologic parameters of 44 infants with NEC were studied at our institution. 232 In 85% of these infants there was gastrointestinal bleeding and 47% were thrombocytopenic, including all of those who died (25%). DIC was present in only 22% of those with thrombocytopenia, suggesting that alternative mechanisms were responsible for the reduction in the platelet count in most instances. Other investigators have reported similar results. 105 Additional features in some of these infants were polycythemia, infection, and hypoxia, all of which may contribute to thrombocytopenia, as may local consumption of platelets in the necrotic bowel wall.
Hemolytic Anemia and Exchange Transfusions
Thrombocytopenia may occur in infants with erythroblastosis fetalis. 37 The mechanism is undefined, but the possibilities include hypersplenism, DIC, and platelet destruction secondary to interaction with procoagulant products of red blood cell lysis. 37 Exchange transfusions in these infants and in others are known to result in thrombocytopenia. This is secondary to dilution by nonviable platelets in stored blood, 109 removal of viable platelets during the process of volume exchange, and a limited ability of the bone marrow to compensate for such an acute deficit.
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Phototherapy
Phototherapy, a common form of treatment for hyperbilirubinemia in the newborn, has been demonstrated to cause a mild thrombocytopenia. 152 In a rabbit model, phototherapy shortened the platelet survival, suggesting that increased destruction was taking place. 152 In vitro experiments have been performed in which platelets were exposed to a broad spectrum blue fluorescent light, with a resulting decrease in aggregation, reduction of glycogen granules and organelles, and loss of definition of the external membranes.
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Intrauterine Growth Retardation and Congenital Polycythemia
Intrauterine growth retarded infants, without other problems, often have a mild degree of thrombocytopenia. 190 Postulated mechanisms include consumption in an infarcted placenta, chronic hypoxia, and DIC.
The association of congenital polycythemia and thrombocytopenia has been described frequently. 87 ' 199 The mechanism has not been determined, but it has been proposed that the increased platelet consumption is induced by the blood hyperviscosity, an hypothesis supported by observations in children having polycythemia secondary to cyanotic congenital heart disease.
Congenital heart disease. Children with cyanotic congenital heart disease frequently have thrombocytopenia when the hemoglobin concentration is greater than 17 gm/dl. 88 Platelet kinetic studies have revealed a reduction in the platelet lifespan, 83 ,246 but DIC does not appear to be the pathogenetic mechanism responsible.
63,101,249
Hypoxia
Hypoxia, a common insult in the newborn period, has been shown to cause a severe and persistent thrombocytopenia in mice. 21 Possible mechanisms are a decreased rate of platelet production or a structural or metabolic defect in the platelets leading to increased destruction. 21 Whether this is an important phenomenon in human neonates has not been determined.
Deficient Plasma Factors
Thrombocytopenia, which is corrected by infusions of plasma, has been reported in both infants 216 and older children. 209, 210, 235 Platelet survival is shortened 235 and a hemolytic anemia may be present as well. In our experience with such a patient, temporary remission has been achieved repeatedly with fresh frozen plasma and infusions of cryoprecipitate but not with albumin. The basic abnormality remains undefined.
Hypersplenism
Hypersplenism occurs in numerous diseases in children, and thrombocytopenia is a well-known complication. The degree of thrombocytopenia is usually mild (50,000 to 100,000/mm 3 ) and exhibits an inverse correlation with the size of the spleen. 18 The use of 51 Cr labeled platelets has demonstrated clearly that splenic "pooling" is responsible for the reduction in the circulating platelet count. 10, 43 Normally, one-third of the total platelet mass is located in the spleen, but in hypersplenic patients up to 90% is contained in this organ. 10 The half-life of the labeled platelets is only minimally decreased, indicating that these are only sequestered in the spleen and not destroyed there prematurely.
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COMBINED IMMUNE-AND NONIMMUNE-MEDIATED PLATELET DESTRUCTION
Infection-Induced Platelet Destruction
Thrombocytopenia has been documented frequently in infants and children who are acutely infected with a variety of microorganisms. 12, 45, 50, 54, 157 Bacterial and viral infections have been studied in greatest detail. In neonates and older children with proved bacterial infections, thrombocytopenia occurs in 60%. 50, 102 This is similar to the frequency reported in adults. 198 Although 25 to 60% of such children have some evidence of DIC, in at least 40% this is not the explanation for the thrombocytopenia. 50 Indeed there is experimental evidence to support other pathogenetic mechanisms, such as endothelial damage by bacteria or bacterial products leading to platelet adhesion and aggregation, 77, 154 platelet aggregation secondary to the binding of bacterial products to platelet membranes, 230 and immune-mediated thrombocytopenia. 126, 183, 227 Kelton et al. 126 have reported that PAIgG is increased in adult patients with documented sepsis, and Tate and his co-workers 227 made an identical observation in eight of nine infants with bacterial infections.
A low platelet count has been reported in association with a wide variety of viral infections in children. 66, 158, 172, 180, 227, 253 Experimental studies indicated that several mechanisms may be involved. These include DIC, 158 virus-induced lysis of red blood cells with the release of procoagulant materials, 34 endothelial damage with increased platelet consumption, 158 platelet phagocytosis of virus particles, 179 loss of sialic acid from the platelet membrane due to the action of viral neuraminidases, 211 intravascular platelet aggregation, 211 immune-mediated platelet destruction, 180, 227 and impaired platelet production. 66, 111, 185 In clinical studies, direct invasion of the megakaryocytes with varicella, 66 cytomegalovirus (CMV), 35 and measles 185 has been reported. Immune-mediated platelet destruction is likely to be an important mechanism, as suggested by the association of a preceding viral infection in the majority of children with acute ITP 38,147,221 and the high level of PAIgG in six of eight infants with documented viral infections. 227 In the latter series, four infants had CMV, two had enteroviral infections, one had herpes simplex virus, and one had an echovirus. Thrombocytopenia due to rubella infection has been studied in some detail. 48 In congenital rubella, 86% of infants have thrombocytopenia, with a majority having counts between 20,000 and 60,000/mm 3 . Serious hemorrhage occurs rarely, and the thrombocytopenia resolves usually by 4 to 8 weeks of age. A decrease in the number of megakaryocytes has been reported in bone marrow aspirates from these infants, but, given the difficulty of obtaining reasonable specimens in the newborn period, it is difficult to interpret this information reliably. Platelet kinetics and platelet-related antibodies have not been measured in these infants. Rubella-induced thrombocytopenia in older children is thought to be immune mediated. 172, 180 The management of infants and older children with thrombocytopenia, which is secondary to infections, will depend on the severity and pathogenesis of the reduction in the platelet count. In the majority of children the thrombocytopenia is mild and no specific treatment for the thrombocytopenia is necessary. For the few in whom intervention is required, infusion of random donor platelets and the administration of corticosteroids have been of benefit in selected cases. 172 '
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COMMENT
Although numerous defined pathologic processes contribute to increased platelet destruction in infancy and childhood, the mechanism responsible for thrombocytopenia may be unclear or multifactorial. Thus, in a recent prospective study of all infants admitted to a neonatal intensive care unit, approximately 10% of whom were appreciably thrombocytopenic (<100,000/mm 3 ) in the first few days of life, no cause for the low platelet count could be identified in the great majority. 26 In this age group in particular, much remains to be learned of the factors that influence platelet turnover and the pathologic events that may lead to exaggerated platelet destruction. 
